Niosome Delivery Systems in Pharmaceutical Applications
Article Sidebar
Main Article Content
Abstract
Niosomes are lamellar non-ionic surfactant vesicles obtained from hydration of synthetic nonionic surfactants,with or without incorporation of cholesterol. Niosomes were first reported in the cosmetic industries. Recently, these vesicular systems can be used as carriers of hydrophillic and lipophilic drugs as liposomes. Niosomes exhibit more chemically stable than liposomes, in which the phospholipid degradation generally occurs. Niosomes are promising vehicle and serve as an alternative drug delivery system. They are less toxic and improve the therapeutic index of drug by restricting its action to target cells. This review article presents an overview of theoretical concept of factors affecting niosome formation, techniques of niosome preparation, evaluation of niosome characterization andpharmaceutical applications of niosome.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Abd-Elbary A, El-laithy HM, Tadros MI. Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm 2008; 357(1-2): 189-198.
Aggarwal D, Garg A, Kaur IP. Development of a topical niosomal preparation of acetazolamide: Preparation and evaluation. J Pharm Pharmacol2004; 56: 1509-1517.
Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system.Int J Pharm2005; 290: 155-159.
Arunothayanun P, Bernard MS, Craig DQ, Uchegbu IF, Florence AT. The effect of processing variables on the physical characteristics of nonionic surfactant vesicles (niosomes) formed from hexadecyl diglycerol ether. Int J Pharm 2000; 201(1): 7-14.
Arunothayanun P, Uchegbu IF, Florence AT.Osmotic behaviour of polyhedral non-ionic surfactant vesicles (niosomes). J Pharm Pharmacol1999; 51(6): 651-7.
Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol1985; 37: 237-242.
Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes- Non-ionic surfactant vesicles. J Pharm Pharmacol 1985; 37: 863-868.
Baillie AJ, Coombs GH, Dolan TF. Non-ionic surfactant vesicles, niosomes, as delivery system for the anti-leishmanial drug, sodium stribogluconate, J Pharm Pharmacol 1986; 38: 502-505.
Balasubramaniam A, Kumar VA, Pillai KS. Formulation and in vivo evaluation of niosome encapsulated daunorubicin hydrochloride. Drug Dev and Ind Pharm 2002; 28: 1181-1193.
Beugin-Deroo S, Ollivon M, Lesieur S. Bilayer stability and impermeability of nonionic surfactant vesicles sterically stabilized by PEG-cholesterol conjugates. J Colloid Interface Sci 1998; 202: 324-333.
Bhaskaran S, Lakshmi PK. Comparative evaluation of niosome formulations prepared by different techniques. Acta Pharm Sci 2009; 51: 27-32.
Bouwstra JA, VanHal DA, Hofland HEJ. Preparation and characterization of nonionic surfactant vesicles.Colloid Surf A Phy Eng Asp 1997; 123-124: 71-80.
Brewer JM, Roberts CW, Conacher M, McColl J, Blarney BA, Alexander J. An adjuvant formulation that preferentially induces T helper cell type 1 cytokine and CD8+cytotoxic responses is associated with up-regulation of IL-12 and suppression of IL-10 production. Vaccine Res 1996; 5: 77-89.
Buckton GH, editor. Interfacial phenomena in Drug Delivery and Targeting. Switzerland: Academic Publishers; 1995. 154-155.
Cable C. An examination of the effects of surface modifications on the physicochemical and biological properties of non-ionic surfactant vesicles. [PhD thesis] Pharmaceutical Sciences, University of Strathclyde. Glasgow: 1989.
Carafa M, Santucci E, Lucania G. Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies. Int J Pharm2002; 231: 21-32.
Cevc G, Schatzlein A, Blume G. Transdermal drug carriers-basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides. J Control Rel 1995; 36: 3-16.
Cevc G, Blume G, Schatzlein A, Gebauer D, Paul A. The skin: A pathway for systemic treatment with patches and lipid-based agent carriers. Adv Drug Del Rev 1996; 18: 349-378.
Chandraprakash KS, Udupa N, Umadevi P, Pillai GK. Effect of macrophage activation on plasma disposition of niosomal 3H-Methotrexate in sarcoma-180 bearing mice. J Drug Target1993; 1(2): 143-145.
Chauhan S, Luorence MJ. The preparation of polyoxyethylene containing non-ionic surfactant vesicles. J Pharm Pharmacol 1989; 41: 6.
Donatella P, Rita M, Antonio R, et al.,In vitro and in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery. Biomed Microdevices, 2007; 9: 421-433.
Dufes C, Gaillard F, Uchegbu IF, Schatzlein AG, Olivier JC, and Muller JM. Glucosetargeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int J Pharm 2004; 285: 77-85.
Florence AT, Arunothayanun P, Kiri S, Bernard MS, Uchegbu IF. Some Theological properties of nonionic surfactant vesicles and the determination of surface hydration. J Phys Chem B 1999; 103: 1995-2000.
Gopinath D, Ravi D, Rao BR, Apte SS, Renuka D, Rambhau D. Ascorbyl palmitate vesicles (Aspasomes): formation, characterization and application. Int J Pharm 2004; 271(1-2): 95-113
Handjani-vila RM, Ribier A, Rondot B, Vanlerberghie G. Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int J cosmet Sci1979; 1(5): 303-314.
Hassan Y, Brewer JM, Alexander J, Jennings R. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMS or NISV deliverysystems. Vaccine 1996; 14: 1581-1589.
Hilgers LA, Zigtermann GJWJ, Snippe H. Immunomodulating properties of amphiphilic agents. In: Kammuller ME, Bioksma N, Sienen W, editors. Autoimmunity and Toxicology, Amsterdam: Elsevier; 1989. 294-306.
Hofland HEJ, Geest VR, Bodde HE, Junginger E, Bouwstra JA. Estradiol Permeation from Nonionic Surfactant Vesicles Through Human Stratum Corneum in Vitro. Pharm Res, 1995; 11: 659-664.
Honeywell-Nguyen PL, Bouwstra JA. The in vitrotransport of pergolide from surfactant-based elastic vesicles through human skin: A suggested mechanism of action. J Control Rel 2003; 86: 145-156.
Hunter CA, Dolan TF, Coombs GH, Baillie AJ. Vasicular systems (niosomes and liposomes) in experimental murine visceral leishmaniasis for delivery of sodium stibogluconate. J Pharm Pharmocol 1988; 40: 161-165.
Kaneshina S, Shibata O, Nakamura M. The effect of pressure on the mutual solubility of a nonionic surfactant water system.Bull Chem SocJapan1982; 55: 951-952.
Khandare JN, Madhavi G, Tamhankar BM. Niosomes novel drug delivery system. The Eastern Pharmacist 1994; 37: 61-64.
Kumar A, Pal J, Jaiswal A, Singh V. Review on niosomes as novel drug delivery system.Int Res J Pharm2011; 2(5): 61-65.
Lakshami PK, Gayathri SD, Bhaskaran S, Sacchdanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: Phase I and phase II studies Indian J Dermatol Venerol Leprol, 2007; 73: 157-161.
Luciani A, Olivier J, Clement OG, Siauve N, Frija G, Cuenod C. Glucose receptor directed stealth niosomes for MR tumor detection: Preliminary studies in mice. Radiology 2002; 225: 123-123.
Luciani A, Olivier JC, Clement O, et al. Glucose-receptor MR imaging of tumors: Study in mice with PEGylated paramagnetic Niosomes. Radiology2004; 231: 135-142.
Malhotra M, Jain NK. Niosomes as Drug Carriers. Indian Drugs 1994; 31(3): 81-86.
Mohamed SE, Alia AB, Marwa MS, Amira MM. Niosomes as a novel pharmaceutical formulation encapsulating the hepatoprotective drug silymarin.Int J Pharm Pharm Sci 2012; 4(1): 549-559.
Mokhtar M, Sammourb OA,Hammad MA, Megrab NA. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm 2008; 361: 104-11.
Murdan S, Gregoriadis G, Florence AT. Sorbitan monostearate/ Polysorbate20 organogels containing niosomes: a delivery vehicle for antigen. Eur J Pharm Sci 1999; 8(3): 177-186.
Naresh RA, Chandrashekhar G, Pillai GK, Udupa N. Antiinflammatory activity of Niosome encapsulated diclofenac sodium with Tween 85 in Arthitic rats. Ind J Pharmacol 1994; 26: 46-48.
Naresh RA, Udupa N, Devi PU. Toxicity and antitumor activity of niosomal bleomycin in tumor bearing mice.Indian J Exp Biol. 1996 Aug; 34(8): 764-72.
Nasseri B, Florence AT. Microtubules formed by capillary extrusion and fusion of surfactant vesicles. Int J Pharm 2003; 266: 91-98.
Ozer AY, Hincal AA, Bouwstra JA.A novel drug delivery system nonionic surfactant vesicles. Eur J Pharm Biopharm 1991; 37: 75-79.
Perrie Y, Barralet JE, McNeil S, Vangala A. Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route. Int J Pharm 2004; 284: 311.
Reddy DN, Udupa N. Formulation and evaluation of oral and transdermal preparations of flurbiprofen and piroxicam incorporated with different carriers. Drug Dev Ind Pharm 1993; 19: 843-852.
Rogerson A, Cummings J, Florence AT. Adriamycin-loaded niosomes-drug entrapment, stability and release. J Microencap 1987; 4: 321-328.
Shahiwala A, Misra A. Studies in topical application of niosomally entrapped nimesulide. J Pharma Sci 2002; 5: 220-225.
Uchegbu IF, Florence AT.Nonionic surfactant vesicles (Niosomes)-physical and pharmaceutical chemistry.Adv Coll Interf Sci 1995; 58:1-55.
Uchegbu IF, Double JA, Turton JA, Florence AT. Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Pharm Res 1995; 12: 1019-1024.
Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998; 172: 33-70.
Uchegbu IF, Schatzlein A, Vanlerberghe G, Morgatini N, Florence AT.Polyhedral Non-ionic Surfactant Vesicles. J Pharm Pharmacol 1997; 49(6): 606-610.
Uchegbu IF, Double JA, Kelland LR, Turton JA, Florence AT.The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models.J Drug Target 1996; 3(5): 399-409.
Unezaki S, Maruyama K, Ishida O, Suginaka A, Hosoda J, Iwatsuru M. Enhanced tumour targeting and improved antitumour activity of doxorubicin by long circulating liposomes containing amphipathic poly(ethylene glycol). Int J Pharm1995; 126: 41-48.
VanHal D, VanRensen A, deVringer T, Junginger H, Bouwstra J. Diffusion of estradiol from non-ionic surfactant vesicles through human stratum corneum in vitro. STP Pharma Sci1996; 6: 72-78.
Vyas SP, Mysore N, Jaitely V, Venkatesan N. Discoidal niosome based controlled ocular delivery of timolol maleate. Pharmazie 1998; 53: 466-469.
Yasin MN, Hussain S, Malik F, et al. Preparation and characterization of chloramphenicol niosomes and comparison with chloramphenicol eye drops (0.5%w/v) in experimental conjunctivitis in albino rabbits. Pak J Pharm Sci 2012; 25(1): 117-121.
Yoshioka T, Sternberg B, Florence AT. Preparation and properties of Vesicles (Niosomes) of sorbitan monoesters (Span-20, Span-40, Span-60 and Span-80) and a Sorbitan Triester (Span-85).Int J Pharm 1994; 105:1-6.
Yoshida H, Lehr CM, Kok W, Junginger HE, Verhoef JC, Bouwistra JA. Niosomes for oral delivery of peptide drugs. J Control Rel 1992; 21: 145-153.